Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade: Specific considerations by device and disease state

American Journal of Cardiology

Volumn 81, Issue 7 A, 1998, Pages

  Kereiakes, Dean J ^a  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; HEPARIN; TIROFIBAN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ATHERECTOMY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0032499269     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00198-2     Document Type: Conference Paper

References (40)

1. Kereiakes DJ, Cabot C, Melsheimer RM, Lincoff AM, Califf RM, Topol EJ. Abciximab-mediated platelet GP IIb/IIIa blockade improves outcomes following multiple interventional technologies: results of the EPILOG trial. (Abstr.) Am J Cardiol 1997;80:9S.
2. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
3. Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Weisman UF, Topol EJ. Abciximab reduces risk of unplanned coronary stent deployment: EPILOG trial results. (Abstr.) Circulation 1997;96(suppl I):I-163.
4. Brener SJ, Barr LA, Burchenal J, Katz S, George BS, Jones AA, Moliterno DJ, Topol EJ. A randomized, placebo controlled trial of abciximab with primary angioplasty for acute MI: The RAPPORT Trial. (Abstr.) Circulation 1997; 96(suppl I):I-473.
5. Zidar JP, Kruse KR, Thel MC, Kereiakes DJ, Muhlestein JB, Davidson CJ, Teirstein PS, Tenaglia A, Yakubov SJ, Popma JJ, Tanguay JF, Kitt, MM, Lorenz TJ, Tcheng JE, Lincoff AM, Califf RM, Topol EJ, for the IMPACT II Investigators. Integrilin for Emergency Coronary Artery Stenting. (Abstr.) J Am Coll Cardiol 1996;27:138A.
6. Kereiakes DJ, Cabot CF, Melsheimer RM, Lincoff AM, Califf RM, Topol EJ. Abciximab reduces emergency bypass surgery following bailout coronary stent deployment: EPILOG trial results. (Abstr.) Am J Cardiol 1997;80:36S.
7. Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Cabot CF, Anderson KM, Weisman HF, Califf RM, Topol EJ, for the EPILOG Trial Investigators. Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent utilization, clinical outcomes and bleeding complications. Circulation (in press).
8. Kereiakes DJ, Lincoff AM, Simoons ML, deBoer MJ, Tcheng JE, Vahanian A, Anderson KM, Weisman HF, Califf RA, Topol EJ. Complementarity of stenting and abciximab for percutaneous coronary intervention (Abstr). J Am Coll Cardiol 1998;31:54A.
9. Cutlip DE, Chauhan M, Lasorda D, Bailey SR, Davidson C, Ito S, Senerchia C, Fitzpatrick M, Kuntz RE. Influence of post-procedural myocardial infarction in late clinical outcome in the stent anti-thrombotic regimen study (STARS). (Abstr.) Circulation 1997;96(suppl I):I-31.
10. 3S blockade with percutaneous coronary intervention. JAMA 1997;278:479-484.
11. Moussa I, DiMario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: Frequency, predictors and clinical outcome. J Am Coll Cardiol 1997;29:6-12.
12. Allabadi D, Bowers TR, Tilli FV, Spybrook M, Breenberg HL, Goldstein JA, Grines CL, Safian RD, O'Neill WW. Multiple stents increases target vessel revascularization rates. (Abstr.) J Am Coll Cardiol 1997;29:276A.
13. Gaxiola E, Vlietstra RE, Browne KF, Ebersole DG, Brenner AS, Weeks TT, Kerensky RA. Six-month follow-up of patients with multiple stents in a single coronary artery. (Abstr.) J Am Coll Cardiol 1997;29:276A.
14. Moussa I, DiMario C, Moses J, Reimers B, Blengino S, Colombo A. Single versus multiple Palmaz-Schatz stent implantation: Immediate and follow-up results. (Abstr.) J Am Coll Cardiol 1997;29:276A.
15. Kornowski R, Mintz GS, Mehran R, Pichard AD, Kent KM, Satler LF, Popma JJ, Hong MK, Laird JR, Bucher TA, Purkayastha D, Leon MB. The "full metal jacket": procedural results and late clinical outcomes after placement of three or more coronary stents. (Abstr.) J Am Coll Cardiol 1997;29:188A.
16. Mathew V, Hasdai D, Holmes DR, Garratt KN, Bell MR, Lerman A, Melby S, Grill DE, Berger PB. Clinical outcome of patients undergoing endoluminal coronary artery reconstruction with three or more stents. J Am Coll Cardiol 1977;30:676-681.
17. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB, Williams DO, King SB, Mark DB, Isner JM, Holmes DR, Ellis SG, Lee KL, Keeler GP, Berdan LG, Hinohara T, Califf RM, for the CAVEAT Study Group. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. N Engl J Med 1993;329:221-227.
18. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in "high risk" coronary angioplasty. N Engl J Med 1994;330:956-961.
19. Baim DS, Cutlip DE, Sharma SK, Ho KKL, Fortuna R, Schreiber TL, Feldman RL, Shani J, Senerchia C, Zhang Y, Lansky AJ, Popma JJ, Kuntz RE, for the BOAT Investigators. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). Circulation 1998;97:322-331.
20. Ghaffari S, Kereiakes DJ, Kelly T, Tcheng JE, Timmis GC, Miller DP, Lincoff AM. Platelet GP IIb/IIIa receptor blockade reduces ischemic complications in patients undergoing directional coronary atherectomy. (Abstr.) Circulation 1996;94(suppl I):I-198.
21. Dehmer GJ, Nichols TC, Bode AP, Liles D, Sigman J, Li S, Koch G, Tate DA, Griggs TR. Assessment of platelet activation by coronary sinus blood sampling during balloon angioplasty and directional coronary atherectomy. Am J Cardiol 1997;80:871-877.
22. Teirstein PS, Warth DC, Haq N, Jenkins NS, McCowan LC, Aubanel-Reidel P, Morris N, Ginsburg R. High speek rotational coronary atherectomy for patients with diffuse coronary artery disease. J Am Coll Cardiol 1991;18:1694-1701.
23. Teirstein PS, Yakubov SJ, Thel MC, Wildermann N, Kereiakes DJ, Popma JJ, Lincoff AM, Tcheng JE, Califf RM, Topol EJ. Platelet IIb/IIIa blockade with integrelin: atherectomy patients. (Abstr.) J Am Coll Cardiol 1996;27:334A.
24. Braden GA, Applegate RJ, Young TM, Love WW, Sane DC. Abciximab decreases both the incidence and magnitude of creatine kinase elevation during rotational atherectomy. (Abstr.) J Am Coll Cardiol 1997;29:499A.
25. Reisman M, Shuman B, Fei R, Dillard D, Nguyen S, Gordon L. Analysis and comparison of platelet aggregation with high-speed rotational atherectomy. (Abstr.) J Am Coll Cardiol 1997;29:186A.
26. Bier JD, Mukherjee SN, Schubert P, Cohen JS, Cupples LA, Jacobs AK. Predictors of no reflow during rotational atherectomy. (Abstr.) Circulation 1996; 94(suppl I):I-249.
27. Sharma SK, Dangas G, Mehran R, Duvvuri S, Kini A, Cocke TP, Kakarala V, Cohen AM, Marmur JD, Ambrose JA. Risk factors for the development of slow flow during rotational coronary atherectomy. Am J Cardiol 1997;80:219-222
28. Challapalli RM, Eisenberg MJ, Sigmon K, Lemberger J, for the EPIC Investigators. Platelet glycoprotein IIb/IIIa monoclonal antibody (c7E3) reduces distal embolization during percutaneous intervention of saphenous vein grafts. (Abstr.) Circulation 1995;92(suppl I):I-607.
29. Tcheng JE, Anderson K, Tardiff BE, Cabot CF, Lincoff AM, Califf RM, Topol EJ. Reducing the risk of percutaneous intervention after coronary bypass surgery: Beneficial effects of abciximab treatment. (Abstr.) J Am Coll Cardiol 1997;29:187A.
30. Lu Y, Theroux P, Xiao Z, Ghitescu M. Increased expression of GP IIb/IIIa platelet membrane receptor in acute ischemic syndromes. (Abstr.) Circulation 1996;94(suppl I):I-515.
31. Eto K, Isshiki T, Nishiyama Y, Takeshita S, Ochiai M, Sato T, Miyashita H. Accelerated primary platelet aggregation in acute myocardial infarction: use of a new aggregometry employing laser-light scattering system. (Abstr.) J Am Coll Cardiol 1997;29:409A.
32. Lincoff AM, Califf RM, Anderson K, Weisman HF, Topol EJ, for the EPIC Investigators. Striking clinical benefit with platelet GP IIb/IIIa inhibition by c7E3 among patients with unstable angina: Outcome in the EPIC trial. (Abstr.) Circulation 1994;90(suppl I):I-21.
33. Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ, for the EPIC Investigators. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997;30:149-156.
34. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. IMPACT II. Lancet 1997;349:1422-1428.
35. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96:1445-1453.
36. Ferguson JJ. Meeting Highlights, 46th Annual Scientific Sessions of the American College of Cardiology - Antiplatelet Therapy in Acute Coronary Syndromes. Circulation 1997;96:367-368.
37. Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: diagnosis and Management. Clinical Practice Guideline Number 10. AHCPR Publication No. 94-0602. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services. March 1994.
38. Eisenstein EL, Peterson ED, Jollis JG, Tardiff BE, Knight JD, Mark DB. Assessing the cost-effectiveness of newer therapies in non-ST elevation acute coronary syndrome patients. (Abstr.) Circulation 1997;96(suppl I):I-183.
39. Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ for the EPIC Investigators. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996;77: 1045-1051.
40. Lincoff AM, Tcheng JE, Miller DP, Booth JE, Montague EA, Topol EJ. Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3 Fab (abciximab) linked to reduction in bleeding complications: Outcomes in the EPILOG and EPIC trials. (Abstr.) Circulation 1996;94(suppl I):I-375.